Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17826659 | 0.84 | KMT2A (0.33) | KMT2ANPC1RAB9AMEN1GABRP | |
| SCHEMBL8998740 | 0.82 | GLA (0.37) | KMT2ANPC1RAB9AMEN1GABRP | |
| SCHEMBL2567865 | 0.78 | CYP1A2 (0.40) | NPC1RAB9AALDH1A1MAPTMAPK1 | |
| SCHEMBL354015 | 0.72 | — | — | |
| SCHEMBL21854498 | 0.72 | L3MBTL1 (0.36) | KMT2ANPC1RAB9AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19119174 | 0.71 | MAPT (0.47) | KMT2ANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL13908278 | 0.70 | — | — | |
| SCHEMBL11329945 | 0.70 | ADORA2A (0.40) | KMT2ANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL23425311 | 0.68 | — | — | |
| SCHEMBL1760311 | 0.68 | ADORA2A (0.36) | KMT2ANPC1RAB9AMEN1GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279215-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED | 2024-08-22 | — | — | US | disclosed |
| EP-4007758-A1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | Mersana Therapeutics, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114585623-A | Bis [ N- ((5-carbamoyl) -1H-benzo [ d ] imidazol-2-yl) pyrazole-5-carboxamide ] derivatives and related compounds as STING (interferon gene stimulator) agonists for the treatment of cancer | 梅尔莎纳医疗公司 | 2022-06-03 | — | — | CN | disclosed |
| US-9365540-B2 | Benzimidazole derivatives as MCH receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2802571-A1 | BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013105676-A1 | BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | WO | disclosed |
| EP-1987030-B1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LTD (GB) | 2011-11-09 | — | — | EP | disclosed |
| US-7691877-B2 | Pharmaceuticals | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| CN-101384593-A | 3-deazapurine derivatives as tlr7 modulators | PFIZER LTD (GB) | 2009-03-11 | — | — | CN | disclosed |
| EP-1987030-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | Pfizer Limited (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093901-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | PFIZER LIMITED | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279215-A1 | NAMPT MODULATORS | NAMPT, SIRT1, NNT | KMT2A 1305/4885NPC1 161/4885RAB9A 360/4885 |
| US-20070197478-A1 | NOVEL PHARMACEUTICALS | TLR3, HAVCR2, TLR9 | KMT2A 4035/4885NPC1 785/4885RAB9A 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.